Anticancer

Canertinib
Catalog No: CFN90010

Canertinib is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Canertinib displays anti-proliferative and pro-apoptotic effects in human myeloid leukemia cells devoid of ErbB-receptors, downregulates important signaling pathways and activates caspase-mediated intrinsic apoptosis pathway in human T-cell leukemia cells.

Gefitinib
Catalog No: CFN90011

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively; it can reduce both cell proliferation and tumor growth of breast cancer cells expressing EGFR and/or HER2. Chronic Gefitinib treatment promotes ROS and mitochondrial dysfunction in lung cancer cells. Antioxidants may alleviate ROS-mediated resistance.

Pinostilbene
Catalog No: CFN98662

Pinostilbene has protective effects against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells, it can reduce release of lactate dehydrogenase and activity of caspase-3 triggered by 6-hydroxydopamine (6-OHDA) in a dose-dependent manner. Pinostilbene can significantly inhibit the growth of human colon cancer cells, i.e., HCT116 and HT29, 20 and 40 uM of pinostilbene causes cell cycle arrest at S phase and induces apoptosis in colon cancer cells.

Catechin 7-xyloside
Catalog No: CFN98665

Catechin-7-O-xyloside has anti-cancer activity, it induces apoptosis via endoplasmic reticulum stress and mitochondrial dysfunction in human non-small cell lung carcinoma H1299 cells.

Santamarine
Catalog No: CFN98667

Santamarine has significant anticancer activity, can inhibit L1210 cells because of its cytotoxic,cytostatic and blocking mitosis and reducing uptake of thymidine. Santamarine and reynosin show bactericidal activity against clinical strains of Mycobacterium tuberculosis.